Biosimilars: Extrapolating the evidence. A roundtable discussion
European Journal of Cancer, Supplement · Published 2015-12-01 · DOI 10.1016/j.ejcsup.2015.12.001
Authors being retrieved — see the publisher record. https://doi.org/10.1016/j.ejcsup.2015.12.001
Abstract
DOAJ holds no abstract for this record.
Read the article at the publisher →
Publication details
- Year
- 2015
Related articles
- Urothelial carcinoma management in elderly or unfit patients · European Journal of Cancer, Supplement · 2016 · Same journal
- Inflammation and immunity in ovarian cancer · European Journal of Cancer, Supplement · 2020 · Same journal
- DNA damaging agents in ovarian cancer · European Journal of Cancer, Supplement · 2020 · Same journal
- The influence of secreted factors and extracellular vesicles in ovarian cancer metastasis · European Journal of Cancer, Supplement · 2020 · Same journal
- Cell proliferation inhibitors and apoptosis promoters · European Journal of Cancer, Supplement · 2020 · Same journal
- Use of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study · European Journal of Cancer, Supplement · 2021 · Same journal
- Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients? · European Journal of Cancer, Supplement · 2021 · Same journal
- Insight updating of the molecular hallmarks in ovarian carcinoma · European Journal of Cancer, Supplement · 2020 · Same journal
- Anti-angiogenic therapy for ovarian cancer · European Journal of Cancer, Supplement · 2020 · Same journal
- Rare ovarian tumours. Other treatments for ovarian cancer · European Journal of Cancer, Supplement · 2020 · Same journal